Skip to main content

NASDAQ:STTK - Shattuck Labs Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $45.60
  • Forecasted Upside: 54.47 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$29.52
▼ -2.48 (-7.75%)
1 month | 3 months | 12 months
Get New Shattuck Labs Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for STTK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for STTK

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$45.60
▲ +54.47% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Shattuck Labs in the last 3 months. The average price target is $45.60, with a high forecast of $75.00 and a low forecast of $34.00. The average price target represents a 54.47% upside from the last price of $29.52.

Buy

The current consensus among 6 contributing investment analysts is to buy stock in Shattuck Labs.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/16/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/14/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/14/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/12/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/10/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/8/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/9/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/9/2021

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/20/2021Berenberg BankInitiated CoverageBuy$47.00Low
i
4/14/2021Berenberg BankInitiated CoverageBuy$47.00High
i
1/20/2021CitigroupBoost Price Target$36.00 ➝ $75.00Medium
i
1/11/2021Evercore ISIInitiated CoverageOutperformLow
i
11/3/2020Smith Barney CitigroupInitiated CoverageBuy$36.00Low
i
11/3/2020CowenInitiated CoverageOutperformHigh
i
11/3/2020Needham & Company LLCInitiated CoverageBuy$34.00High
i
11/3/2020Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellInitiated CoverageBuy$36.00High
i
(Data available from 5/9/2016 forward)
Shattuck Labs logo
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also holds a collaboration agreement with Takeda Pharmaceuticals to develop SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.
Read More

Today's Range

Now: $29.52
$29.20
$32.48

50 Day Range

MA: $31.38
$27.21
$37.68

52 Week Range

Now: $29.52
$17.51
$60.52

Volume

119,786 shs

Average Volume

138,052 shs

Market Capitalization

$1.23 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Shattuck Labs?

The following sell-side analysts have issued stock ratings on Shattuck Labs in the last year: Berenberg Bank, Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, Cowen Inc, Evercore ISI, Needham & Company LLC, Smith Barney Citigroup, and Zacks Investment Research.
View the latest analyst ratings for STTK.

What is the current price target for Shattuck Labs?

5 Wall Street analysts have set twelve-month price targets for Shattuck Labs in the last year. Their average twelve-month price target is $45.60, suggesting a possible upside of 54.5%. Citigroup Inc. has the highest price target set, predicting STTK will reach $75.00 in the next twelve months. Needham & Company LLC has the lowest price target set, forecasting a price of $34.00 for Shattuck Labs in the next year.
View the latest price targets for STTK.

What is the current consensus analyst rating for Shattuck Labs?

Shattuck Labs currently has 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe STTK will outperform the market and that investors should add to their positions of Shattuck Labs.
View the latest ratings for STTK.

What other companies compete with Shattuck Labs?

How do I contact Shattuck Labs' investor relations team?

The company's listed phone number is 919 864 2700 and its investor relations email address is [email protected] The official website for Shattuck Labs is www.shattucklabs.com.